Document is current

Any future updates will be listed below

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12890-025-03509-z

Published Online: 2025-02-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark